Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medistem has collaborated with Shanghai Jia Fu Medical Apparatus, Chinese conglomerate, to develop the Endometrial Regenerative Cell (ERC) universal donor stem cell product for the Chinese market.
Subscribe to our email newsletter
The collaboration initially focuses on treating critical limb ischemia, an advanced form of peripheral artery disease.
Medistem will provide ERC stem cells for research use and Shanghai Jia Fu Medical Apparatus will support ongoing experiments.
All data generated will be provided to Medistem.
Medistem has received FDA clearance to begin a Phase I clinical trial using the ERC stem cells in the patient population.
Medistem CEO Thomas Ichim said Shanghai Jia Fu Medical Apparatus Inc is actively working in the area of clinical translation of cellular therapy.
"We believe this group is an ideal partner for our entry into development of therapeutics for the Chinese population," Ichim added.